Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties

Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor...

Full description

Saved in:
Bibliographic Details
Published inNPJ systems biology and applications Vol. 10; no. 1; pp. 20 - 13
Main Authors van Genderen, Maisa N. G., Kneppers, Jeroen, Zaalberg, Anniek, Bekers, Elise M., Bergman, Andries M., Zwart, Wilbert, Eduati, Federica
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 21.02.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.
AbstractList Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.
Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, “pro-inflammatory” M1-like and “pro-tumor” M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.
Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, "pro-inflammatory" M1-like and "pro-tumor" M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but response may be temporary, in which case resistance develops, ultimately leading to lethal castration-resistant prostate cancer (CRPC). The tumor microenvironment (TME) plays an important role in the development and progression of PCa. In addition to tumor cells, TME-resident macrophages and fibroblasts express AR and are therefore also affected by ADT. However, the interplay of different TME cell types in the development of CRPC remains largely unexplored. To understand the complex stochastic nature of cell-cell interactions, we created a PCa-specific agent-based model (PCABM) based on in vitro cell proliferation data. PCa cells, fibroblasts, "pro-inflammatory" M1-like and "pro-tumor" M2-like polarized macrophages are modeled as agents from a simple set of validated base assumptions. PCABM allows us to simulate the effect of ADT on the interplay between various prostate TME cell types. The resulting in vitro growth patterns mimic human PCa. Our PCABM can effectively model hormonal perturbations by ADT, in which PCABM suggests that CRPC arises in clusters of resistant cells, as is observed in multifocal PCa. In addition, fibroblasts compete for cellular space in the TME while simultaneously creating niches for tumor cells to proliferate in. Finally, PCABM predicts that ADT has immunomodulatory effects on macrophages that may enhance tumor survival. Taken together, these results suggest that AR plays a critical role in the cellular interplay and stochastic interactions in the TME that influence tumor cell behavior and CRPC development.
ArticleNumber 20
Author Zaalberg, Anniek
Bergman, Andries M.
Zwart, Wilbert
van Genderen, Maisa N. G.
Bekers, Elise M.
Eduati, Federica
Kneppers, Jeroen
Author_xml – sequence: 1
  givenname: Maisa N. G.
  orcidid: 0000-0002-7394-9888
  surname: van Genderen
  fullname: van Genderen, Maisa N. G.
  organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121
– sequence: 2
  givenname: Jeroen
  surname: Kneppers
  fullname: Kneppers, Jeroen
  organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121
– sequence: 3
  givenname: Anniek
  surname: Zaalberg
  fullname: Zaalberg, Anniek
  organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121
– sequence: 4
  givenname: Elise M.
  surname: Bekers
  fullname: Bekers, Elise M.
  organization: Division of Pathology, Netherlands Cancer Institute, Plesmanlaan 121
– sequence: 5
  givenname: Andries M.
  orcidid: 0000-0001-5223-2549
  surname: Bergman
  fullname: Bergman, Andries M.
  email: a.bergman@nki.nl
  organization: Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121
– sequence: 6
  givenname: Wilbert
  orcidid: 0000-0002-9823-7289
  surname: Zwart
  fullname: Zwart, Wilbert
  email: w.zwart@nki.nl
  organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513
– sequence: 7
  givenname: Federica
  orcidid: 0000-0002-7822-3867
  surname: Eduati
  fullname: Eduati, Federica
  email: f.eduati@tue.nl
  organization: Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38383542$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUjVARfdAfYIEisWET8DueFaoqHpUqsYG15dg3GY8Se7CdqfoB_DdOZ1raLiovbNnnnHt87zmtjnzwUFXvMPqEEZWfE8OcoQYR1iBEGWvEq-qEIC6aFsvV0aPzcXWe0gYhhAVlBKM31TGVZXFGTqq_FwP43HQ6ga2nYGF0fqhDX-c11NsYUtYZ6jxPIdaTMzGA37kY_FRY9exN2EFMddrq7PR4wA0x3OR1bYJPOWrnc6q1t7WbptmHUmMedQ7xdpHfQswO0tvqda_HBOeH_az6_e3rr8sfzfXP71eXF9eN4QznBrCWHRE9J53tWtGBRZQLZo3kvOMdQcjotheyRUSAkCtGgbTCMGwpRiu7omfV1V7XBr1R2-gmHW9V0E7dXYQ4KF0MmRGUMRaRlsm2J4ZJoFpgi0nHkJSs58CK1pe91nbuJrCmNCTq8Yno0xfv1moIO4WLBOZEFoWPB4UY_syQsppcMjCO2kOYkyIrilhbZrtAPzyDbsIcfelVQS042bLF0vvHlh683I-7AMgeUAaZUoT-AYKRWmKl9rFSJVbqLlZKFJJ8RjKupMKF5VtufJlK99RU6vgB4n_bL7D-AXSD5GU
CitedBy_id crossref_primary_10_3389_fphys_2024_1473125
crossref_primary_10_1016_j_jtbi_2025_112048
crossref_primary_10_3389_fphys_2024_1491144
Cites_doi 10.1080/2162402X.2018.1462431
10.1053/j.seminoncol.2014.03.004
10.1177/0037549717699072
10.1158/1078-0432.CCR-06-0067
10.1002/pros.23742
10.1016/j.ces.2007.11.024
10.1016/j.ccell.2020.06.005
10.1016/j.matcom.2016.05.008
10.1158/0008-5472.CAN-17-2006
10.1038/bjc.2011.385
10.1007/7651_2016_346
10.1038/s41388-018-0583-7
10.1016/j.lfs.2019.116791
10.1007/s00262-007-0343-y
10.3322/caac.21660
10.1038/nrc3245
10.1186/s12943-019-0976-4
10.1371/journal.pone.0047045
10.1530/ERC-18-0042
10.1189/jlb.0609385
10.1371/journal.pcbi.1004025
10.3389/fimmu.2020.519383
10.1111/j.1742-1241.2011.02799.x
10.1038/s41467-020-18313-y
10.1073/pnas.1115750108
10.1038/bjc.2013.748
10.1158/1541-7786.MCR-20-0740
10.1158/0008-5472.CAN-12-3228
10.1016/j.ccell.2021.09.005
10.1002/cbin.11528
10.1155/2022/8580043
10.1158/1078-0432.CCR-18-0461
10.1371/journal.pone.0122827
10.1158/2767-9764.CRC-23-0097
10.1111/j.1464-410X.2010.09804.x
10.1073/pnas.1815735116
10.1016/j.jtbi.2010.02.027
10.1063/1.3697848
10.1016/j.tcb.2022.10.006
10.1088/1478-3975/9/1/016002
10.1186/1475-2867-5-8
10.1158/0008-5472.CAN-18-1126
10.1016/j.semcancer.2008.03.004
10.1016/j.humpath.2010.02.011
10.7554/eLife.76284
10.1002/1878-0261.12327
10.1210/er.2002-0032
10.1371/journal.pone.0060562
10.3390/cancers14194923
10.1038/onc.2013.191
10.1016/j.cell.2018.11.021
10.1002/pros.20927
10.4049/jimmunol.1800352
10.1200/JCO.2002.10.018
10.1038/s41388-019-0805-7
10.1038/s41467-022-33780-1
10.1007/s00332-008-9031-0
10.1200/CCI.18.00057
10.1080/10446670310001626580
10.1101/2023.06.06.543873
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41540-024-00344-6
DatabaseName Springer Nature OA/Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE


Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central (ProQuest)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2056-7189
EndPage 13
ExternalDocumentID oai_doaj_org_article_ccd027487f2c48e3a61d12b40884f5e4
PMC10881528
38383542
10_1038_s41540_024_00344_6
Genre Journal Article
GrantInformation_xml – fundername: Oncode Institute
GroupedDBID 0R~
5VS
7X7
8FE
8FH
8FI
AAJSJ
AASML
ABUWG
ACGFS
ADBBV
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
EBLON
EBS
FYUFA
GROUPED_DOAJ
HCIFZ
HYE
KQ8
LK8
M7P
M~E
NAO
NO~
OK1
PGMZT
PIMPY
PQQKQ
PROAC
PUEGO
RNT
RPM
SNYQT
UKHRP
8FJ
AAYXX
CCPQU
CITATION
HMCUK
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AARCD
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c541t-e1a8b26f52bdb76bed03564dc855b5b200ca7f687026e68943e276c41d3109d93
IEDL.DBID 7X7
ISSN 2056-7189
IngestDate Wed Aug 27 01:30:39 EDT 2025
Thu Aug 21 18:35:22 EDT 2025
Thu Jul 10 22:44:32 EDT 2025
Wed Aug 13 03:26:52 EDT 2025
Mon Jul 21 05:50:35 EDT 2025
Thu Apr 24 22:58:06 EDT 2025
Tue Jul 01 01:18:36 EDT 2025
Sun Aug 31 08:58:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-e1a8b26f52bdb76bed03564dc855b5b200ca7f687026e68943e276c41d3109d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-7394-9888
0000-0002-7822-3867
0000-0002-9823-7289
0000-0001-5223-2549
OpenAccessLink https://www.proquest.com/docview/2929308744?pq-origsite=%requestingapplication%
PMID 38383542
PQID 2929308744
PQPubID 2041915
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_ccd027487f2c48e3a61d12b40884f5e4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10881528
proquest_miscellaneous_2930473448
proquest_journals_2929308744
pubmed_primary_38383542
crossref_primary_10_1038_s41540_024_00344_6
crossref_citationtrail_10_1038_s41540_024_00344_6
springer_journals_10_1038_s41540_024_00344_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-02-21
PublicationDateYYYYMMDD 2024-02-21
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-21
  day: 21
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle NPJ systems biology and applications
PublicationTitleAbbrev npj Syst Biol Appl
PublicationTitleAlternate NPJ Syst Biol Appl
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Kather (CR46) 2017; 77
Poleszczuk, Macklin, Enderling (CR42) 2016; 1516
Cioni (CR30) 2020; 11
Poleszczuk, Hahnfeldt, Enderling (CR41) 2015; 11
Kirby, Hirst, Crawford (CR57) 2011; 65
Becerra-Díaz, Strickland, Keselman, Heller (CR31) 2018; 201
Olumi (CR12) 1999; 59
Zhang (CR18) 2020; 38
Erlandsson (CR50) 2019; 79
Frascoli, Flood, Kim (CR43) 2017; 34
He (CR63) 2019; 38
Henshall (CR25) 2001; 61
Fang (CR27) 2013; 73
Ideta, Tanaka, Takeuchi, Aihara (CR37) 2008; 18
Heinlein, Chang (CR3) 2004; 25
Kfoury (CR15) 2021; 39
Tanaka, Hirata, Goldenberg, Bruchovsky, Aihara (CR38) 2010; 368
Chiarugi, Paoli, Cirri (CR62) 2014; 41
Zhang, Cunningham, Brown, Gatenby (CR34) 2022; 11
Portz, Kuang, Nagy (CR36) 2012; 2
Ab Wahab, Nefti-Meziani, Atyabi (CR66) 2015; 10
Enot, Vacchelli, Jacquelot, Zitvogel, Kroemer (CR69) 2018; 7
Payne, Mason (CR56) 2011; 105
Lissbrant (CR28) 2000; 17
Ayala (CR60) 2003; 9
Yang, Fung, Day, Kropp, Lin (CR4) 2005; 5
Cioni, Zwart, Bergman (CR22) 2018; 25
Andreoiu, Cheng (CR58) 2010; 41
Comito (CR49) 2014; 33
Sung (CR1) 2021; 71
Rohrs, Wang, Finley (CR29) 2019; 3
West, Robertson-Tessi, Anderson (CR40) 2023; 33
CR59
Geldhof, van Ginderachter, Liu, Noël, de Baetselier (CR53) 2003; 10
Hirata, Bruchovsky, Aihara (CR35) 2010; 264
Sun, Wu, He, He, Sun (CR20) 2019; 235
Wikström, Marusic, Stattin, Bergh (CR8) 2009; 69
Nagasaki (CR16) 2014; 110
Pourhasanzade, Sabzpoushan, Alizadeh, Esmati (CR44) 2017; 93
Passier (CR48) 2023; 3
Kather (CR47) 2018; 78
Jalalimanesh, Haghighi, Ahmadi, Soltani (CR45) 2017; 133
Consiglio, Gollnick (CR32) 2020; 11
Neal (CR14) 2018; 175
Edin (CR23) 2012; 7
Siefert (CR24) 2021; 19
Singer (CR61) 2013; 8
Lorenzo, Hughes, Dominguez-Frojan, Reali, Gomez (CR33) 2019; 116
Han (CR52) 2022; 2022
Wong (CR11) 2022; 13
Solinas, Germano, Mantovani, Allavena (CR54) 2009; 86
Schwaab, Biscaia, Monteiro, Pinto (CR67) 2008; 63
Cioni (CR26) 2018; 12
Sica (CR21) 2008; 18
Pienta, Bradley (CR5) 2006; 12
Wei (CR55) 2019; 18
Kumar (CR10) 2022; 14
Nonomura (CR13) 2011; 107
Tu, Dou, Wang, Zhuang, Zhang (CR51) 2021; 45
Gelmann (CR2) 2002; 20
Olapade-Olaopa (CR7) 1999; 5
Tan, Bora (CR68) 2017; 11
Ippolito (CR19) 2019; 38
CR65
Lazar (CR64) 2012; 9
Jain, Clinton, Bhinder, Friedman (CR39) 2011; 108
Huang (CR9) 2018; 24
Croci (CR17) 2007; 56
Fridman, Pagès, Sautès-Fridman, Galon (CR6) 2012; 12
H Sung (344_CR1) 2021; 71
AM Ideta (344_CR37) 2008; 18
A Jalalimanesh (344_CR45) 2017; 133
V Kumar (344_CR10) 2022; 14
B Cioni (344_CR30) 2020; 11
N Nonomura (344_CR13) 2011; 107
E Singer (344_CR61) 2013; 8
344_CR65
AF Olumi (344_CR12) 1999; 59
Z Zhang (344_CR18) 2020; 38
DC Lazar (344_CR64) 2012; 9
M Becerra-Díaz (344_CR31) 2018; 201
P Chiarugi (344_CR62) 2014; 41
L-Y Fang (344_CR27) 2013; 73
H Payne (344_CR56) 2011; 105
L Ippolito (344_CR19) 2019; 38
DO Croci (344_CR17) 2007; 56
J Poleszczuk (344_CR42) 2016; 1516
F Frascoli (344_CR43) 2017; 34
AB Geldhof (344_CR53) 2003; 10
P Wikström (344_CR8) 2009; 69
T Portz (344_CR36) 2012; 2
M Kirby (344_CR57) 2011; 65
Q Yang (344_CR4) 2005; 5
B Cioni (344_CR22) 2018; 25
HY Wong (344_CR11) 2022; 13
344_CR59
KJ Pienta (344_CR5) 2006; 12
G Tanaka (344_CR38) 2010; 368
M Andreoiu (344_CR58) 2010; 41
T Nagasaki (344_CR16) 2014; 110
JN Kather (344_CR46) 2017; 77
JA Rohrs (344_CR29) 2019; 3
HV Jain (344_CR39) 2011; 108
WH Fridman (344_CR6) 2012; 12
S Edin (344_CR23) 2012; 7
C Wei (344_CR55) 2019; 18
G Lorenzo (344_CR33) 2019; 116
JN Kather (344_CR47) 2018; 78
CR Consiglio (344_CR32) 2020; 11
DP Enot (344_CR69) 2018; 7
CA Heinlein (344_CR3) 2004; 25
D-Y Sun (344_CR20) 2019; 235
B Cioni (344_CR26) 2018; 12
IF Lissbrant (344_CR28) 2000; 17
F Pourhasanzade (344_CR44) 2017; 93
Y Hirata (344_CR35) 2010; 264
EO Olapade-Olaopa (344_CR7) 1999; 5
H Huang (344_CR9) 2018; 24
A Sica (344_CR21) 2008; 18
G Ayala (344_CR60) 2003; 9
Y He (344_CR63) 2019; 38
J West (344_CR40) 2023; 33
Y Kfoury (344_CR15) 2021; 39
G Comito (344_CR49) 2014; 33
J Zhang (344_CR34) 2022; 11
G Solinas (344_CR54) 2009; 86
RK Tan (344_CR68) 2017; 11
SM Henshall (344_CR25) 2001; 61
M Passier (344_CR48) 2023; 3
MN Ab Wahab (344_CR66) 2015; 10
D Tu (344_CR51) 2021; 45
EP Gelmann (344_CR2) 2002; 20
J Poleszczuk (344_CR41) 2015; 11
M Schwaab (344_CR67) 2008; 63
C Han (344_CR52) 2022; 2022
JC Siefert (344_CR24) 2021; 19
JT Neal (344_CR14) 2018; 175
A Erlandsson (344_CR50) 2019; 79
References_xml – volume: 7
  start-page: e1462431
  year: 2018
  ident: CR69
  article-title: TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1462431
– volume: 41
  start-page: 267
  year: 2014
  end-page: 280
  ident: CR62
  article-title: Tumor microenvironment and metabolism in prostate cancer
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2014.03.004
– volume: 93
  start-page: 641
  year: 2017
  end-page: 657
  ident: CR44
  article-title: An agent-based model of avascular tumor growth: Immune response tendency to prevent cancer development
  publication-title: Simulation
  doi: 10.1177/0037549717699072
– volume: 17
  start-page: 445
  year: 2000
  end-page: 451
  ident: CR28
  article-title: Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival
  publication-title: Int. J. Oncol.
– volume: 368
  start-page: 5029
  year: 2010
  end-page: 5044
  ident: CR38
  article-title: Mathematical modelling of prostate cancer growth and its application to hormone therapy.
  publication-title: Phys. Eng. Sci.
– volume: 12
  start-page: 1665
  year: 2006
  end-page: 1671
  ident: CR5
  article-title: Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-0067
– volume: 79
  start-page: 363
  year: 2019
  end-page: 369
  ident: CR50
  article-title: M2 macrophages and regulatory T cells in lethal prostate cancer
  publication-title: The Prostate
  doi: 10.1002/pros.23742
– volume: 63
  start-page: 1542
  year: 2008
  end-page: 1552
  ident: CR67
  article-title: Nonlinear parameter estimation through particle swarm optimization
  publication-title: Chem. Eng. Sci.
  doi: 10.1016/j.ces.2007.11.024
– volume: 38
  start-page: 279
  year: 2020
  end-page: 296.e9
  ident: CR18
  article-title: Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.06.005
– volume: 133
  start-page: 235
  year: 2017
  end-page: 248
  ident: CR45
  article-title: Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning
  publication-title: Math. Comput. Simul.
  doi: 10.1016/j.matcom.2016.05.008
– volume: 77
  start-page: 6442
  year: 2017
  end-page: 6452
  ident: CR46
  article-title: In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2006
– volume: 105
  start-page: 1628
  year: 2011
  end-page: 1634
  ident: CR56
  article-title: Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2011.385
– volume: 1516
  start-page: 335
  year: 2016
  end-page: 346
  ident: CR42
  article-title: Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth
  publication-title: Methods Mol. Biol.
  doi: 10.1007/7651_2016_346
– volume: 38
  start-page: 2337
  year: 2019
  end-page: 2350
  ident: CR63
  article-title: Androgen Signaling is Essential for Development of Prostate Cancer Initiated From Prostatic Basal Cells
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0583-7
– volume: 235
  start-page: 116791
  year: 2019
  ident: CR20
  article-title: Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2019.116791
– volume: 59
  start-page: 5002
  year: 1999
  end-page: 5011
  ident: CR12
  article-title: Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium
  publication-title: Cancer Res.
– volume: 56
  start-page: 1687
  year: 2007
  end-page: 1700
  ident: CR17
  article-title: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-007-0343-y
– volume: 71
  start-page: 209
  year: 2021
  end-page: 249
  ident: CR1
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 12
  start-page: 298
  year: 2012
  end-page: 306
  ident: CR6
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3245
– volume: 18
  year: 2019
  ident: CR55
  article-title: Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0976-4
– volume: 7
  start-page: e47045
  year: 2012
  ident: CR23
  article-title: The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0047045
– volume: 25
  start-page: R331
  year: 2018
  end-page: R349
  ident: CR22
  article-title: Androgen receptor moonlighting in the prostate cancer microenvironment
  publication-title: Endocr. Rel. Cancer
  doi: 10.1530/ERC-18-0042
– volume: 86
  start-page: 1065
  year: 2009
  end-page: 1073
  ident: CR54
  article-title: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
  publication-title: J. Leukocyte Biol.
  doi: 10.1189/jlb.0609385
– volume: 11
  start-page: e1004025
  year: 2015
  ident: CR41
  article-title: Evolution and Phenotypic Selection of Cancer Stem Cells
  publication-title: PLOS Comput. Biol.
  doi: 10.1371/journal.pcbi.1004025
– volume: 11
  start-page: 519383
  year: 2020
  ident: CR32
  article-title: Androgen Receptor Signaling Positively Regulates Monocytic Development
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.519383
– volume: 65
  start-page: 1180
  year: 2011
  end-page: 1192
  ident: CR57
  article-title: Characterising the castration-resistant prostate cancer population: a systematic review
  publication-title: Int. J. Clin. Pract.
  doi: 10.1111/j.1742-1241.2011.02799.x
– volume: 11
  year: 2020
  ident: CR30
  article-title: Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18313-y
– volume: 108
  start-page: 19701
  year: 2011
  end-page: 19706
  ident: CR39
  article-title: Mathematical modeling of prostate cancer progression in response to androgen ablation therapy
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1115750108
– volume: 110
  start-page: 469
  year: 2014
  end-page: 478
  ident: CR16
  article-title: Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2013.748
– volume: 19
  start-page: 1778
  year: 2021
  end-page: 1791
  ident: CR24
  article-title: The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-20-0740
– volume: 73
  start-page: 5633
  year: 2013
  end-page: 5646
  ident: CR27
  article-title: Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-3228
– volume: 9
  start-page: 4792
  year: 2003
  end-page: 4801
  ident: CR60
  article-title: Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer
  publication-title: Clin. Cancer Res.
– volume: 39
  start-page: 1464
  year: 2021
  end-page: 1478.e8
  ident: CR15
  article-title: Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.09.005
– volume: 45
  start-page: 831
  year: 2021
  end-page: 838
  ident: CR51
  article-title: M2 macrophages contribute to cell proliferation and migration of breast cancer
  publication-title: Cell Biol. Int.
  doi: 10.1002/cbin.11528
– volume: 2022
  start-page: 8580043
  year: 2022
  ident: CR52
  article-title: The Roles of Tumor-Associated Macrophages in Prostate Cancer
  publication-title: J. Oncol.
  doi: 10.1155/2022/8580043
– volume: 24
  start-page: 4612
  year: 2018
  end-page: 4626
  ident: CR9
  article-title: Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0461
– volume: 10
  start-page: e0122827
  year: 2015
  ident: CR66
  article-title: A comprehensive review of swarm optimization algorithms
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0122827
– volume: 3
  start-page: 1473
  year: 2023
  end-page: 1485
  ident: CR48
  article-title: Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model
  publication-title: Cancer Res. Commun.
  doi: 10.1158/2767-9764.CRC-23-0097
– volume: 107
  start-page: 1918
  year: 2011
  end-page: 1922
  ident: CR13
  article-title: Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer
  publication-title: BJU Int.
  doi: 10.1111/j.1464-410X.2010.09804.x
– volume: 116
  start-page: 1152
  year: 2019
  end-page: 1161
  ident: CR33
  article-title: Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1815735116
– volume: 264
  start-page: 517
  year: 2010
  end-page: 527
  ident: CR35
  article-title: Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2010.02.027
– volume: 2
  start-page: 011002
  year: 2012
  ident: CR36
  article-title: A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy
  publication-title: AIP Adv.
  doi: 10.1063/1.3697848
– volume: 33
  start-page: 300
  year: 2023
  end-page: 311
  ident: CR40
  article-title: Agent-based methods facilitate integrative science in cancer
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2022.10.006
– volume: 5
  start-page: 569
  year: 1999
  end-page: 576
  ident: CR7
  article-title: Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma
  publication-title: Clin. Cancer Res.
– volume: 9
  start-page: 016002
  year: 2012
  ident: CR64
  article-title: Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line
  publication-title: Phys. Biol.
  doi: 10.1088/1478-3975/9/1/016002
– volume: 5
  year: 2005
  ident: CR4
  article-title: Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival
  publication-title: Cancer Cell Int.
  doi: 10.1186/1475-2867-5-8
– volume: 78
  start-page: 5155
  year: 2018
  end-page: 5163
  ident: CR47
  article-title: High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer.
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-1126
– volume: 18
  start-page: 349
  year: 2008
  end-page: 355
  ident: CR21
  article-title: Macrophage polarization in tumour progression
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2008.03.004
– volume: 41
  start-page: 781
  year: 2010
  end-page: 793
  ident: CR58
  article-title: Multifocal prostate cancer: biologic, prognostic, and therapeutic implications
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2010.02.011
– ident: CR65
– volume: 11
  start-page: e76284
  year: 2022
  ident: CR34
  article-title: Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes
  publication-title: eLife
  doi: 10.7554/eLife.76284
– volume: 12
  start-page: 1308
  year: 2018
  end-page: 1323
  ident: CR26
  article-title: Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12327
– volume: 34
  start-page: 215
  year: 2017
  end-page: 240
  ident: CR43
  article-title: A model of the effects of cancer cell motility and cellular adhesion properties on tumour-immune dynamics
  publication-title: Math. Med. Biol.
– volume: 25
  start-page: 276
  year: 2004
  end-page: 308
  ident: CR3
  article-title: Androgen receptor in prostate cancer
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2002-0032
– volume: 8
  start-page: e60562
  year: 2013
  ident: CR61
  article-title: Stromal Response to Prostate Cancer: Nanotechnology-Based Detection of Thioredoxin-Interacting Protein Partners Distinguishes Prostate Cancer Associated Stroma from That of Benign Prostatic Hyperplasia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0060562
– volume: 14
  start-page: 4923
  year: 2022
  ident: CR10
  article-title: Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk
  publication-title: Cancers
  doi: 10.3390/cancers14194923
– volume: 33
  start-page: 2423
  year: 2014
  end-page: 2431
  ident: CR49
  article-title: Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression
  publication-title: Oncogene
  doi: 10.1038/onc.2013.191
– volume: 175
  start-page: 1972
  year: 2018
  end-page: 1988.e16
  ident: CR14
  article-title: Organoid Modeling of the Tumor Immune Microenvironment
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.021
– volume: 69
  start-page: 799
  year: 2009
  end-page: 809
  ident: CR8
  article-title: Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients
  publication-title: Prostate
  doi: 10.1002/pros.20927
– volume: 201
  start-page: 2923
  year: 2018
  end-page: 2933
  ident: CR31
  article-title: Androgen and Androgen Receptor as Enhancers of M2 Macrophage Polarization in Allergic Lung Inflammation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1800352
– volume: 20
  start-page: 3001
  year: 2002
  end-page: 3015
  ident: CR2
  article-title: Molecular biology of the androgen receptor
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.10.018
– volume: 10
  start-page: 71
  year: 2003
  end-page: 81
  ident: CR53
  article-title: Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation
  publication-title: J. Immunol. Res.
– ident: CR59
– volume: 61
  start-page: 423
  year: 2001
  end-page: 427
  ident: CR25
  article-title: Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer
  publication-title: Cancer Res.
– volume: 38
  start-page: 5339
  year: 2019
  end-page: 5355
  ident: CR19
  article-title: Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0805-7
– volume: 13
  year: 2022
  ident: CR11
  article-title: Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33780-1
– volume: 18
  start-page: 593
  year: 2008
  ident: CR37
  article-title: A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer
  publication-title: J. Nonlinear Sci.
  doi: 10.1007/s00332-008-9031-0
– volume: 3
  start-page: 1
  year: 2019
  end-page: 8
  ident: CR29
  article-title: Understanding the Dynamics of T-Cell Activation in Health and Disease Through the Lens of Computational Modeling
  publication-title: JCO Clin. Cancer Inform.
  doi: 10.1200/CCI.18.00057
– volume: 11
  start-page: 1314
  year: 2017
  end-page: 1323
  ident: CR68
  article-title: Parameter Tuning of Complex Systems Modeled in Agent Based Modeling and Simulation
  publication-title: Int. J. Comput. Inf. Eng.
– volume: 38
  start-page: 5339
  year: 2019
  ident: 344_CR19
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0805-7
– volume: 133
  start-page: 235
  year: 2017
  ident: 344_CR45
  publication-title: Math. Comput. Simul.
  doi: 10.1016/j.matcom.2016.05.008
– volume: 201
  start-page: 2923
  year: 2018
  ident: 344_CR31
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1800352
– volume: 116
  start-page: 1152
  year: 2019
  ident: 344_CR33
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1815735116
– volume: 175
  start-page: 1972
  year: 2018
  ident: 344_CR14
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.021
– volume: 11
  start-page: e76284
  year: 2022
  ident: 344_CR34
  publication-title: eLife
  doi: 10.7554/eLife.76284
– volume: 18
  year: 2019
  ident: 344_CR55
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0976-4
– volume: 69
  start-page: 799
  year: 2009
  ident: 344_CR8
  publication-title: Prostate
  doi: 10.1002/pros.20927
– volume: 93
  start-page: 641
  year: 2017
  ident: 344_CR44
  publication-title: Simulation
  doi: 10.1177/0037549717699072
– volume: 13
  year: 2022
  ident: 344_CR11
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33780-1
– volume: 33
  start-page: 300
  year: 2023
  ident: 344_CR40
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2022.10.006
– volume: 7
  start-page: e47045
  year: 2012
  ident: 344_CR23
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0047045
– volume: 5
  year: 2005
  ident: 344_CR4
  publication-title: Cancer Cell Int.
  doi: 10.1186/1475-2867-5-8
– volume: 3
  start-page: 1473
  year: 2023
  ident: 344_CR48
  publication-title: Cancer Res. Commun.
  doi: 10.1158/2767-9764.CRC-23-0097
– volume: 2022
  start-page: 8580043
  year: 2022
  ident: 344_CR52
  publication-title: J. Oncol.
  doi: 10.1155/2022/8580043
– volume: 25
  start-page: R331
  year: 2018
  ident: 344_CR22
  publication-title: Endocr. Rel. Cancer
  doi: 10.1530/ERC-18-0042
– volume: 45
  start-page: 831
  year: 2021
  ident: 344_CR51
  publication-title: Cell Biol. Int.
  doi: 10.1002/cbin.11528
– volume: 18
  start-page: 593
  year: 2008
  ident: 344_CR37
  publication-title: J. Nonlinear Sci.
  doi: 10.1007/s00332-008-9031-0
– volume: 73
  start-page: 5633
  year: 2013
  ident: 344_CR27
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-3228
– volume: 12
  start-page: 1665
  year: 2006
  ident: 344_CR5
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-0067
– volume: 19
  start-page: 1778
  year: 2021
  ident: 344_CR24
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-20-0740
– volume: 38
  start-page: 2337
  year: 2019
  ident: 344_CR63
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0583-7
– volume: 41
  start-page: 781
  year: 2010
  ident: 344_CR58
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2010.02.011
– volume: 10
  start-page: e0122827
  year: 2015
  ident: 344_CR66
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0122827
– volume: 12
  start-page: 298
  year: 2012
  ident: 344_CR6
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3245
– volume: 3
  start-page: 1
  year: 2019
  ident: 344_CR29
  publication-title: JCO Clin. Cancer Inform.
  doi: 10.1200/CCI.18.00057
– volume: 11
  year: 2020
  ident: 344_CR30
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18313-y
– volume: 86
  start-page: 1065
  year: 2009
  ident: 344_CR54
  publication-title: J. Leukocyte Biol.
  doi: 10.1189/jlb.0609385
– volume: 7
  start-page: e1462431
  year: 2018
  ident: 344_CR69
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1462431
– volume: 368
  start-page: 5029
  year: 2010
  ident: 344_CR38
  publication-title: Phys. Eng. Sci.
– volume: 61
  start-page: 423
  year: 2001
  ident: 344_CR25
  publication-title: Cancer Res.
– volume: 41
  start-page: 267
  year: 2014
  ident: 344_CR62
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2014.03.004
– volume: 20
  start-page: 3001
  year: 2002
  ident: 344_CR2
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.10.018
– volume: 63
  start-page: 1542
  year: 2008
  ident: 344_CR67
  publication-title: Chem. Eng. Sci.
  doi: 10.1016/j.ces.2007.11.024
– volume: 264
  start-page: 517
  year: 2010
  ident: 344_CR35
  publication-title: J. Theor. Biol.
  doi: 10.1016/j.jtbi.2010.02.027
– volume: 235
  start-page: 116791
  year: 2019
  ident: 344_CR20
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2019.116791
– volume: 11
  start-page: e1004025
  year: 2015
  ident: 344_CR41
  publication-title: PLOS Comput. Biol.
  doi: 10.1371/journal.pcbi.1004025
– volume: 9
  start-page: 016002
  year: 2012
  ident: 344_CR64
  publication-title: Phys. Biol.
  doi: 10.1088/1478-3975/9/1/016002
– volume: 11
  start-page: 1314
  year: 2017
  ident: 344_CR68
  publication-title: Int. J. Comput. Inf. Eng.
– volume: 56
  start-page: 1687
  year: 2007
  ident: 344_CR17
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-007-0343-y
– volume: 18
  start-page: 349
  year: 2008
  ident: 344_CR21
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2008.03.004
– volume: 12
  start-page: 1308
  year: 2018
  ident: 344_CR26
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12327
– ident: 344_CR65
– volume: 10
  start-page: 71
  year: 2003
  ident: 344_CR53
  publication-title: J. Immunol. Res.
  doi: 10.1080/10446670310001626580
– ident: 344_CR59
  doi: 10.1101/2023.06.06.543873
– volume: 107
  start-page: 1918
  year: 2011
  ident: 344_CR13
  publication-title: BJU Int.
  doi: 10.1111/j.1464-410X.2010.09804.x
– volume: 24
  start-page: 4612
  year: 2018
  ident: 344_CR9
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0461
– volume: 110
  start-page: 469
  year: 2014
  ident: 344_CR16
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2013.748
– volume: 105
  start-page: 1628
  year: 2011
  ident: 344_CR56
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2011.385
– volume: 108
  start-page: 19701
  year: 2011
  ident: 344_CR39
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1115750108
– volume: 33
  start-page: 2423
  year: 2014
  ident: 344_CR49
  publication-title: Oncogene
  doi: 10.1038/onc.2013.191
– volume: 65
  start-page: 1180
  year: 2011
  ident: 344_CR57
  publication-title: Int. J. Clin. Pract.
  doi: 10.1111/j.1742-1241.2011.02799.x
– volume: 9
  start-page: 4792
  year: 2003
  ident: 344_CR60
  publication-title: Clin. Cancer Res.
– volume: 39
  start-page: 1464
  year: 2021
  ident: 344_CR15
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.09.005
– volume: 77
  start-page: 6442
  year: 2017
  ident: 344_CR46
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2006
– volume: 38
  start-page: 279
  year: 2020
  ident: 344_CR18
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.06.005
– volume: 17
  start-page: 445
  year: 2000
  ident: 344_CR28
  publication-title: Int. J. Oncol.
– volume: 2
  start-page: 011002
  year: 2012
  ident: 344_CR36
  publication-title: AIP Adv.
  doi: 10.1063/1.3697848
– volume: 14
  start-page: 4923
  year: 2022
  ident: 344_CR10
  publication-title: Cancers
  doi: 10.3390/cancers14194923
– volume: 5
  start-page: 569
  year: 1999
  ident: 344_CR7
  publication-title: Clin. Cancer Res.
– volume: 1516
  start-page: 335
  year: 2016
  ident: 344_CR42
  publication-title: Methods Mol. Biol.
  doi: 10.1007/7651_2016_346
– volume: 78
  start-page: 5155
  year: 2018
  ident: 344_CR47
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-1126
– volume: 25
  start-page: 276
  year: 2004
  ident: 344_CR3
  publication-title: Endocr. Rev.
  doi: 10.1210/er.2002-0032
– volume: 8
  start-page: e60562
  year: 2013
  ident: 344_CR61
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0060562
– volume: 71
  start-page: 209
  year: 2021
  ident: 344_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 59
  start-page: 5002
  year: 1999
  ident: 344_CR12
  publication-title: Cancer Res.
– volume: 34
  start-page: 215
  year: 2017
  ident: 344_CR43
  publication-title: Math. Med. Biol.
– volume: 11
  start-page: 519383
  year: 2020
  ident: 344_CR32
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.519383
– volume: 79
  start-page: 363
  year: 2019
  ident: 344_CR50
  publication-title: The Prostate
  doi: 10.1002/pros.23742
SSID ssj0001634210
Score 2.2819602
Snippet Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients, but...
Abstract Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT) reduces prostate cancer (PCa) growth in virtually all patients,...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 20
SubjectTerms 631/553
631/67
692/4028
Androgen Antagonists
Androgen receptors
Androgens
Bioinformatics
Biomedical and Life Sciences
Castration
Cell interactions
Cell proliferation
Computational Biology/Bioinformatics
Computer Appl. in Life Sciences
Fibroblasts
Growth patterns
Humans
Immunomodulation
Immunomodulators
Inflammation
Life Sciences
Macrophages
Male
Prostate - pathology
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - pathology
Receptors, Androgen - metabolism
Systems Analysis
Systems Biology
Tumor cells
Tumor Microenvironment
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNH06SYsKvbUiq6e1xzQkhEJ7aiA3oZebQGMva-8hP6D_uzOyd7vb56U-WrI8aGaYGWnmG0LeNMaKGBvPQmMDU9Im5vk8s6wiOAvZz21pNvHxk7m4VB-u9NVWqy_MCRvhgceNO44xYeRk60ZEZbP0hicuggLtUI3OBQkUbN5WMFVOV4xUEMxMVTIzaY97sFSYySgUKzB3zOxYogLY_zsv89dkyZ9uTIshOn9EHk4eJD0ZKd8n93L7mNwfe0rePSHfTrBYiqF1SrT0uYFVaNdQ8PToAms8wLukw-q2W9JbzMbbKnWjYOQwpbOnPSZaw1_GeV8gVh-uaURfEltKDD31baI3WFvSwT-wBVi3vMPlF5innfun5PL87PPpBZt6LbCoFR9Y5t4GYRotQgq1CTnNpDYqRat10AF0KfoaGFtDzJYNgrZnUZuoeEJo0TSXz8he27X5BaG15EKkZEXmSeno_TyqyEOYqdhIeCrC1_vu4gREjsR_deVCXFo38soBr1zhlTMVebv5ZjHCcPx19ntk52YmQmiXFyBYbhIs9y_BqsjRWhjcpNe9E-BNIoaiguHXm2HQSLxm8W3uVjgHrzKBEFuR56PsbCiRVuJJm6iI3ZGqHVJ3R9qb64L6zYEwcLZg0XdrAfxB15_34uB_7MUheSCK5ggm-BHZG5ar_BKcsSG8Knr3HR0UMnk
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: HAS SpringerNature Open Access 2022
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiHcDBRmJG1isH3G8xwVRVSvBBSr1ZvmVthJNVpvsoT-A_82Mk2xZKEjkGE-cUWYmM7ZnviHkTa2NCKF2zNfGMyVNZI7PE0sqQLCQ3NzkZhOfv-iTU7U8K8_2iJhqYXLSfoa0zL_pKTvsfQeOBhMRhWIZpY7pO-QAodpBtw8Wi-XX5c3OipYKFjJjhcxMmlse3vFCGaz_tgjzz0TJ305LsxM6fkDuj9EjXQz8PiR7qXlE7g79JK8fkx8LLJRi6JkizT1uYBba1hSiPLrC-g6ILGm_uWrX9Aoz8X4pc6Pg4DCds6MdJlnDWwa6c1in9xc0YByJ7ST6jrom0kusK2nhHdj-q11f4_QrzNFO3RNyevzp28cTNvZZYKFUvGeJO-OFrkvho6-0T3EmS61iMGXpSw92FFwFQq1gvZY0ArYnUemgeERY0TiXT8l-0zbpkNBKciFiNCLxqMrg3DyowL2fqVBLuArCp-9uwwhCjsx_t_kwXBo7yMqCrGyWldUFebt9ZjVAcPyT-gOKc0uJ8Nn5Rrs-t6M62RAiLsdNVYugTJJO88iFV_DLVXWZVEGOJmWwo013VkAkifiJCoZfb4fBGvGIxTWp3SANHmMCI6Ygzwbd2XIijcRdNlEQs6NVO6zujjSXFxnxmwNjEGjBpO8mBbzh6-_f4vn_kb8g90S2EcEEPyL7_XqTXkLI1ftXo439BHF_KUo
  priority: 102
  providerName: Springer Nature
Title Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties
URI https://link.springer.com/article/10.1038/s41540-024-00344-6
https://www.ncbi.nlm.nih.gov/pubmed/38383542
https://www.proquest.com/docview/2929308744
https://www.proquest.com/docview/2930473448
https://pubmed.ncbi.nlm.nih.gov/PMC10881528
https://doaj.org/article/ccd027487f2c48e3a61d12b40884f5e4
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDBa2FgN2Gfaety7QgN02odHDsnIa0qBFEWDFsK1Abob1cFugtbPYOfQH7H-PlJ1k6SuXALYiMyYpUiL5kZDPpTbCubJgtjSWKWk8K_gosKAcOAuhGJnYbOL7iT4-VdNZOusP3Jo-rXK1JsaF2tcOz8j3BdhxRK9T6tv8D8OuURhd7VtoPCa7CF2GUp3Nss0Zi5YKtjR9rcxQmv0G7BXmMwrFItgd01v2KML23-Vr3k6ZvBE3jebo6Dl51vuRdNwx_gV5FKqX5EnXWfL6Ffk7xpIphjbK09jtBmahdUnB36NzrPQAH5O2y6t6Qa8wJ--_gjcKpg4TOxvaYLo1PKUbdwY79vacOvQosbFE29Ci8vQCK0xqeAY2AqsX1zj9HLO1Q_OanB4d_p4cs77jAnOp4i0LvDBW6DIV1ttM2-CHMtXKO5OmNrWgUa7IgL0Z7NyCRuj2IDLtFPcIMOpH8g3ZqeoqvCM0k1wI740I3KvUFcXIKcetHSpXSvgkhK_ee-56OHIk_jKPYXFp8o5XOfAqj7zKdUK-rH8z78A4Hhx9gOxcj0Qg7XihXpzlvV7mznncmJusFE6ZIAvNPRdWweKryjSohOythCHvtbvJN7KYkE_r26CXGGwpqlAvcQwGNIEQk5C3neysKZFG4nmbSIjZkqotUrfvVBfnEfubA2HgcsGkX1cCuKHr_nfx_uG_8YE8FVEnBBN8j-y0i2X4CM5WawdRowZkdzye_prC98HhyY-fcHWiJ4N4gPEPhbMvSQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxLspBYwEJ7C6dpzEe0CoPKotfZxaaW8mfqStRJPtJqtqfwB_h9_IjJPssjx66x43jjPJjGfGnplvCHldpEpYW-TMFMowGSvHcj70zEsLzoLPhyo0mzg8Skcn8us4Ga-Rn30tDKZV9joxKGpXWTwj3xZgxxG9TsoPk0uGXaMwutq30GjFYt_Pr2DLVr_f-wz8fSPE7pfjTyPWdRVgNpG8YZ7nyoi0SIRxJkuNd4M4SaWzKklMYkBqbJ7BK2SwO_EpwpN7kaVWcocgmg7Bl0Dl3wLDO8DNXjbOlmc6aSxhC9XV5gxitV2DfcT8SSFZANdj6Yr9C20C_uXb_p2i-UecNpi_3fvkXue30p1W0B6QNV8-JLfbTpbzR-THDpZoMbSJjobuOjALrQoK_iWdYGUJ-LS0mV1UU3qBOYC_FdhRMK2YSFrTGtO74SntuNNpddWcUYseLDayaGqal46eY0VLBc_AxmPVdI7TTzA73NePycmN8OIJWS-r0m8QmsVcCOeU8NzJxOb50ErLjRlIW8Twiwjvv7u2Hfw5Ev9dhzB8rHTLKw280oFXOo3I28U9kxb849rRH5Gdi5EI3B3-qKanutMD2lqHBwEqK4SVysd5yh0XRoKyl0XiZUS2emHQnTap9VL2I_JqcRn0AAZ38tJXMxyDAVQgREXkaSs7C0piFeP5noiIWpGqFVJXr5TnZwFrnANh4OLBpO96AVzS9f9vsXn9a7wkd0bHhwf6YO9o_xm5K8L6EEzwLbLeTGf-OTh6jXkRVhcl3256Of8CeH1mMA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1Jo6gXhB3JcxwEjwBFZrx0ncB4Q2tmpjUE2ISXsL8SXbJJZ0TaqpH8BP8XWc4yQt5bK35TFxnOOcq31uhLzKYyWMyTOmc6WZDJVlGR865qQBY8FlQ-WbTXwex_vH8uNJdLJGfna5MBhW2clEL6htafCMvC9Aj2P1Oin7eRsWcbQ7ej-5ZNhBCj2tXTuNhkQO3fwKtm_Vu4NdwPVrIUZ7Xz_ss7bDADOR5DVzPFNaxHkktNVJrJ0dhFEsrVFRpCMNFGSyBJaTwE7FxViq3IkkNpJbLKhpsRATiP_1BHdFPbK-szc--rI84YlDCRuqNlNnEKp-BdoSoymFZL7UHotXtKFvGvAvS_fvgM0_vLZeGY7ukbutFUu3G7K7T9Zc8YDcavpazh-SH9uYsMVQQ1rqe-3ALLTMKVibdIJ5JmDh0np2UU7pBUYE_pZuR0HRYlhpRSsM9oavNONOp-VVfUYN2rPY1qKuaFZYeo75LSV8A9uQldM5Tj_BWHFXPSLHN4KNx6RXlIXbIDQJuRDWKuG4lZHJsqGRhms9kCYP4QoI7_57atpi6Aj899Q75UOVNrhKAVepx1UaB-TN4p1JUwrk2tE7iM7FSCzj7W-U09O0lQqpMRaPBVSSCyOVC7OYWy60BNEv88jJgGx1xJC2sqVKl5wQkJeLxyAV0NWTFa6c4Rh0pwIgKiBPGtpZQBKqEE_7REDUClWtgLr6pDg_85XHOQAGBh9M-rYjwCVc__8Xm9cv4wW5DaycfjoYHz4ld4RnD8EE3yK9ejpzz8Dqq_Xzlr0o-XbTHP0LSldryw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Agent-based+modeling+of+the+prostate+tumor+microenvironment+uncovers+spatial+tumor+growth+constraints+and+immunomodulatory+properties&rft.jtitle=NPJ+systems+biology+and+applications&rft.au=van+Genderen%2C+Maisa+N+G&rft.au=Kneppers%2C+Jeroen&rft.au=Zaalberg%2C+Anniek&rft.au=Bekers%2C+Elise+M&rft.date=2024-02-21&rft.issn=2056-7189&rft.eissn=2056-7189&rft.volume=10&rft.issue=1&rft.spage=20&rft_id=info:doi/10.1038%2Fs41540-024-00344-6&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-7189&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-7189&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-7189&client=summon